Merck pays $250M to license Moderna cancer vaccine
Bio Pharma Dive
OCTOBER 12, 2022
The drugmaker’s decision to grab rights to the shot deepens its ties with the COVID-19 vaccine developer and comes weeks before a key data release.
mRNA licensing agreements surge 800% amid GSK lawsuits
Pharmaceutical Technology
OCTOBER 18, 2024
An 800% increase in licensing deal values indicates growing confidence in mRNA technology, but some vaccine producers are facing lawsuits.
Licensing 
279
279 Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Takeda nabs option to license Alzheimer’s immunotherapies from AC Immune
Bio Pharma Dive
MAY 13, 2024
The deal — worth $100 million up front and potentially billions more later on — gives Takeda an exclusive option to license an Alzheimer’s vaccine and other “active immunotherapies.”
Licensing 201
201 
CureVac cuts jobs, licenses out vaccines to GSK
Bio Pharma Dive
JULY 3, 2024
The mRNA specialist plans to eliminate 30% of its workforce as part of a restructuring that will prioritize “high-value” projects like its cancer vaccines.
Vaccine 176
176 
Sanofi signs $1.2bn licensing agreement for Novavax’s Covid-19 vaccine
Pharmaceutical Technology
MAY 10, 2024
Sanofi has signed a $1.2bn licensing agreement with Novavax to co-commercialise its stand-alone adjuvanted Covid-19 vaccine.
Licensing 130
130 
Dyadic expands Covid-19 licence with Rubic to bolster vaccine production in Africa
Pharmaceutical Technology
APRIL 13, 2023
The expanded licence will include the development of vaccines and therapeutic proteins beyond Covid-19 for human and animal health markets in Africa. During the Covid-19 pandemic, vaccination rates of many countries in Africa were significantly trailing the rest of the world.
Production 280
280 
Moderna pays US government $400M 'catch-up payment' under new COVID-19 vaccine license
Fierce Pharma
FEBRUARY 24, 2023
Moderna pays US government $400M 'catch-up payment' under new COVID-19 vaccine license esagonowsky Fri, 02/24/2023 - 09:18
Licensing 145
145 
BARDA awards contract for Sabin’s Ebola Sudan and Marburg virus vaccines
Pharmaceutical Technology
JANUARY 13, 2023
The Biomedical Advanced Research and Development Authority (BARDA) has awarded a multi-year contract to the Sabin Vaccine Institute for developing and producing single-dose vaccine candidates for Ebola Sudan and Marburg virus diseases. Currently, there are no licensed vaccines against these viruses.
Vaccine 246
246 
GreenLight and US NIH partner to develop Covid-19 vaccine for variants
Pharmaceutical Technology
AUGUST 1, 2022
GreenLight Biosciences has entered a partnership with the US National Institutes of Health (NIH) for the development of Covid-19 vaccines, which offer broader protection against new variants and with durable effects. They intend to develop vaccines that provide lasting immune responses compared to existing vaccines.
Vaccine 245
245 
India’s CDSCO approves Bharat Biotech’s intra-nasal vaccine for Covid-19
Pharmaceutical Technology
DECEMBER 2, 2022
India’s Central Drugs Standard Control Organisation (CDSCO) has granted approval for Bharat Biotech’s BBV154 vaccine for treating Covid-19. BBV154 is claimed to be the first intra-nasal vaccine for Covid-19 in the world.
Vaccine 217
217 
Oral COVID-19 vaccine beckons, as ImmunityBio licenses iosBio tech
pharmaphorum
JANUARY 12, 2021
ImmunityBio has licensed technology underpinning a COVID-19 vaccine that could be administered orally rather than by injection from UK biotech iosBio. One of the primary advantages of this approach is that the oral vaccine capsules are stable at room temperature, which means they do not require cold chain storage.
Licensing 119
119 
Mandating vaccinations is the right decision
World of DTC Marketing
SEPTEMBER 10, 2021
The government has the latitude to protect citizens from deadly conditions, especially when the science supporting vaccination is so clear” We, as a nation, can not allow ignorance and stupidity to endanger us all. It is reckless at this point for the government not to mandate vaccination.
Vaccine 191
191 
Meningitis vaccine comes to the forefront with impressive study results
Pharmaceutical Technology
MAY 25, 2023
A new vaccine developed by the Serum Institute of India to fight meningococcal disease could help eliminate meningitis across Africa. The results from a trial, published in The New England Journal of Medicine , found the vaccine was associated with a strong immune response and good safety profile. percentage points (96% CI, −0.3
Vaccine 195
195 
India's role in coronavirus vaccine manufacturing grows with new deals
Bio Pharma Dive
AUGUST 6, 2020
The Serum Institute, one of the world's largest vaccine producers, licensed Novavax's experimental shot, while Wockhardt signed on with the U.K. to help make AstraZeneca's candidate.
Vaccine 162
162 
GSK and CureVac restructure mRNA vaccine development deal
Pharmaceutical Technology
JULY 3, 2024
GSK and CureVac have announced the restructuring of their existing partnership into a new licensing agreement for mRNA vaccine candidates.
Vaccine 130
130 
F.D.A. Aims for Full Approval of Pfizer Covid Vaccine on Monday
NY Times
AUGUST 20, 2021
Federal regulators are winding down the process of licensing Pfizer’s two-dose coronavirus vaccine, setting up an approval possibly by Monday and possibly kicking off a wave of new mandates.
Vaccine 145
145 
Swiss startup LimmaTech licenses GSK vaccine, hires ex-CureVac chief as CEO
Bio Pharma Dive
JULY 20, 2023
The startup will take on development of a shigellosis vaccine GSK inherited when it acquired LimmaTech’s predecessor, GlycoVaxyn, in 2015.
Vaccine 130
130 
LakeShore commences BLA submission to DRAP for rabies vaccine
Pharmaceutical Technology
NOVEMBER 8, 2024
LakeShore Biopharma has commenced the submission of its biologics license application (BLA) to the Drug Regulatory Authority of Pakistan (DRAP) seeking conditional approval for its PIKA Rabies Vaccine for post-exposure prophylaxis (PEP).
Vaccine 130
130 
NIH licenses COVID-19 technologies to WHO-backed program
Bio Pharma Dive
MAY 13, 2022
The agreement, which covers three experimental vaccines as well as several key patents, will be royalty free for products sold in 49 low-income countries.
Licensing 157
157 
Sanofi forges $1.2bn alliance with vaccines firm Novavax
pharmaphorum
MAY 10, 2024
Sanofi has licensed joint commercial rights to Novavax’s COVID-19 vaccine and will work with the biotech on the development of combined flu/COVID shots in a deal worth up to $1.2
Vaccine 115
115 
Moderna Q1 reveals COVID-19 vaccine sales stats: Biologics License Application to be submitted this month
BioPharma Reporter
MAY 6, 2021
The next step will be to start a rolling submission for a Biologics License Application (BLA) for its COVID-19 vaccine with the FDA this month. Moderna has reported the first profitable quarter in the companyâs history: after 10 years of research and several billion dollars of investment in its mRNA platform.
Licensing 94
94 
South Korea authorises Novavax Covid-19 vaccine as booster dose
Pharmaceutical Technology
JANUARY 19, 2023
The Korean Ministry of Food and Drug Safety (KMFDS) has granted expanded approval to Novavax partner SK bioscience for the Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), for use as a booster dose in adults aged 18 and above. Nuvaxovid is a protein-based vaccine created from the genetic sequence of the initial SARS-CoV-2 virus strain.
Vaccine 148
148 
Moderna’s COVID-Flu Combo Shot Beats Separate Vaccines in Phase III Study
BioSpace
JUNE 10, 2024
Moderna’s combination vaccine candidate for COVID-19 and influenza outperformed licensed vaccines in older adults, according to late-stage results reported on Monday.
Vaccine 107
107 
Evaxion and ExpreS²ion partner to develop new CMV vaccine
Pharmaceutical Technology
DECEMBER 6, 2022
Evaxion Biotech and ExpreS 2 ion Biotechnologies have entered a vaccine discovery collaboration agreement to co-develop a new cytomegalovirus (CMV) vaccine candidate. Until 2025, the companies will equally share the research and intellectual property licensing expenses under the partnership.
Vaccine 130
130 
GSK’s shingles vaccine Shingrix gains UK license
Pharma Times
SEPTEMBER 2, 2021
Jab aimed at adults aged 50 years and older and those at increased risk
Licensing 118
118 
Valneva, LimmaTech ally on quest for first Shigella vaccine
pharmaphorum
AUGUST 1, 2024
Valneva has bolstered its vaccines pipeline with a shot designed to protect against shigellosis – a major global health threat – licensed from LimmaTech Biologics.The French pharma company – best known for its COVID-19 jab and recent approval for the world's first chikungunya vaccine Ixchiq – is paying €10 million upfront for a stake in LimmaTech's (..)
Vaccine 105
105 
Opinion: Will low-dose vaccination stretch the monkeypox vaccine supply, or backfire?
STAT News
AUGUST 9, 2022
heath secretary recently declared monkeypox as a public health emergency , paving the way for emergency use authorizations of additional vaccines or vaccine regimens to fight the disease. The same day, Food and Drug Administration Commissioner Robert Califf said that the U.S. — by changing the way it is given.
Vaccine 105
105 
Chinese tech giant Baidu licenses mRNA algorithm to Sanofi
pharmaphorum
NOVEMBER 23, 2021
Sanofi has bolstered its push into mRNA-based therapies with a new licensing deal – but not as might be expected with some up-and-coming biotech company. Sanofi is the first pharma company to partner with Baidu on its LinearDesign AI platform, which has been developed specifically to optimise the sequence of mRNA-based vaccines and drugs.
Licensing 105
105 
CSL bets on mRNA vaccines in deal with Arcturus
Bio Pharma Dive
NOVEMBER 2, 2022
The drugmaker agreed to pay $200 million upfront and potentially billions more to license the technology and knowhow from Arcturus to make preventive shots for COVID-19, influenza and other respiratory infections.
Licensing 157
157 
STAT+: Merck pays $250 million to license a Moderna skin-cancer vaccine candidate
STAT News
OCTOBER 12, 2022
Merck on Wednesday agreed to extend an ongoing collaboration with Moderna to develop a personalized vaccine for the treatment of patients with skin cancer. Moderna is getting $250 million from Merck to secure opt-in rights to the cancer vaccine candidate, called mRNA-4157.
Vaccine 98
98 
Does Pfizer have a conscience?
World of DTC Marketing
FEBRUARY 11, 2022
Pfizer has held a vaccine monopoly, blocking low-income countries from accessing its novel technology, while enriching shareholders at levels advocates for vaccine equity label “obscene.” Sure they developed a vaccine but isn’t it a moral responsibility to share it with the world? The Atlantic ). How much profit is enough?
Vaccine 212
212 
FDA decision on Pfizer’s maternal RSV vaccine expected by August
BioPharma Reporter
FEBRUARY 21, 2023
The US Food and Drug Administration (FDA) has accepted Pfizerâs Biologics License Application (BLA) for its maternal RSV vaccine under priority review. If approved, the vaccine will become the first RSV vaccine for pregnant women to protect against RSV in infants.
Vaccine 98
98 
Pfizer and BioNTech seek FDA EUA for Omicron-based Covid-19 vaccine
Pharmaceutical Technology
AUGUST 23, 2022
5-adapted bivalent vaccine for Covid-19 in people aged 12 years and above. 1-adapted vaccine. The FDA also sought the vaccine’s pre-clinical and manufacturing data for addressing the SARS-CoV-2 virus’ evolution. 5-adapted bivalent vaccine will be made readily available for shipping. 5-adapted bivalent vaccine.
Vaccine 130
130 
CanSinoBIO developed a highly effective COVID vaccine with an inhalant version
pharmaphorum
JULY 18, 2022
MBA, managing director at CanSino Biologics Europe, tells us about Convidecia, a single dose SARS-CoV-2 vaccine offered as an injectable and inhalant that allows ease of storage, an alternative option for individuals with needle phobias, and robust elongated CD4 and CD8 cellular response. Morgon, PharmD, LL.M, How it works. Regarding the BA.4
Vaccine 138
138 
COVID-19 News: Vaxart Posts Phase I Data on Oral Vaccine, BMS Licenses mAb
BioSpace
FEBRUARY 2, 2021
The vast majority of COVID-19 vaccines on the market or in development are administered through an injection, but Vaxart is attempting to develop an oral vaccine.
Vaccine 90
90 
FDA grants priority review for Pfizer COVID-19 vaccine BLA
BioPharma Reporter
JULY 19, 2021
The US Food and Drug Administration (FDA) has granted priority review designation for Pfizer and BioNTechâs COVID-19 vaccine Biologics License Application (BLA).
Vaccine 98
98 
Opinion: How small vaccine stockpiles can stop outbreaks of infectious disease from becoming big
STAT News
APRIL 24, 2023
Marburg could soon become the second virus in the past year to have experimental vaccine candidates ready for testing under an emergency use listing. Until this point, no licensed vaccines or treatments are available for Marburg. Read the rest…
Vaccine 111
111 
FDA expected to make decision on Pfizer RSV vaccine in May
BioPharma Reporter
DECEMBER 8, 2022
The US Food and Drug Administration (FDA) has accepted Pfizerâs RSV vaccine Biologics License Application (BLA) for priority review: with a decision expected in May.
Vaccine 98
98 
FDA Approves First Measles Vaccine in Half a Century
BioSpace
JUNE 5, 2022
GSK's MMR vaccine is only the second to be approved in the United States for protection against measles, mumps and rubella. The first, licensed to Merck, was approved in 1971.
FDA Approval 96
96 
Vaccibody and Genentech in cancer vaccine R&D and commercialization tie-up
BioPharma Reporter
OCTOBER 1, 2020
Oslo headquartered, Vaccibody, a pioneer in the neoantigen cancer vaccine space, has entered into an exclusive worldwide license and collaboration agreement with Genentech.
Vaccine 97
97 
Ocugen turns to BLA path in the US for COVID-19 vaccine candidate
BioPharma Reporter
JUNE 14, 2021
Ocugen will pursue submission of a biologics license application (BLA) in the US for the COVID-19 vaccine candidate, COVAXIN, rather than a EUA application. The company believes that the differentiated vaccine has the potential to address variants, as well as planning to undertake paediatric and booster trials.
Vaccine 98
98 
Pfizer Buys Stake in Valneva to Advance Lyme Disease Vaccine
BioSpace
JUNE 19, 2022
They also updated their Collaboration and License deal for a Lyme disease vaccine that was announced in April. Pfizer inked an Equity Subscription Agreement with France-based Valneva.
Vaccine 94
94 
Malaria Vaccine a Breakthrough Success with 77 Percent Efficacy
XTalks
APRIL 26, 2021
After years of disappointing malaria vaccine trials, a malaria shot developed by researchers at the Jenner Institute at the University of Oxford has demonstrated an unprecedentedly high efficacy of 77 percent, and may be the magic bullet the world has been waiting for against the deadly disease.
Vaccine 105
105 
Let's personalize your content